Member Info for Zoom0001

Strangely enough, this feels like a safer bet than some other AIM stocks to me at this level. They have contracts, pipeline, are owed nearly 9 million and have recently invested circa 9 million in to autonomous production with the potential to produce circa 100 million tests PA. All this for a market cap of 12.5 million.

The market clearly doesn’t like something at the moment though.

A business update would be good. The silence either suggests that either there isn’t a lot going on or, they’ve got their heads down working on existing and new opportunities. I would like to know where they are up to with Vatic.

https://www.biosure.co.uk/tests/covid-19-antigen-test/

According to the Biosure website, the Knowknow test is available to order. Not sure if this is old news.

HL 110.97 to buy and 11.00 to sell.

It can be transmitted via respiratory drops. My guess is that an LFT could be developed but I’m no expert.

*6000

Wonder if we’ll get an RNS next week. Avacta collaborates with Cytiva for a monkeypox assay, followed by Affimers shipped, followed by Affimers can neutralise monkeypox, followed by a commercial partnership with the Kamani’s, followed by APAC production and distribution partners, followed by home use approval, followed by sorry chaps it doesn’t work.

I’m here for AVA600.

I guess interpretations of excellent differ somewhat.

I actually agree with what you say to an extent Pumky and if you’re sitting on a loss you have a right to feel disgruntled. What I don’t really understand is why you talk your investment down multiple times a day. If I thought things were going to get worse here I would cut my losses and put the capital elsewhere.

Avacta’s a completely different investment. There are a few trust issues here but in my opinion the BOD are doing what they can to turn the corner. Last weeks deal is a good example.

Court ruling before expected before the summer and Vatic will happen when it happens. What more can they say?

The current pandemic has put LFT technology on the map and Abingdon have lots of plates spinning in a growing sector.

Personally, I think it will come good here but it is bloody depressing at the moment.

AKA Joe Hond (vaporised) AKA cowthehelldoiknow on Twitter.

Panic mode if your newly invested. A small blip if you’ve been here a long time. My expectations are tempered for mid-year and if all goes well, the manipulation, panic selling and daily traders won’t be able to keep a lid on what’s coming.

Just listened to the VOX interview again. AS states mid year end Q2 for 1a dose escalation & Q3 for expansion.

I’m surprised by the lack of reaction to yesterdays news. A significant, unexpected contract worth approximately a fith of the market cap & we’re sub 12p. Defies logic.

Anyway, no need to panic. According to some on Twitter, silence is golden and it works. That’s we thought about the LFT and the silence turned out to be brown.

Much more confident with AVA600 but hope we don’t have to wait too long for an update.

I would have thought an RNS would be worthy for either option. The market expects dose escalation and unless I’ve missed it, I don’t recall Avacta giving guidance to the contrary.

Sorry, this one.

https://www.londonstockexchange.com/news-article/EUA/new-director-appointed/15457004

https://www.londonstockexchange.com/news-article/EUA/restoration-of-trading/15456763

Beautiful poetry. Clever use of the word sausage.